Metformin doesn't improve breast cancer survival in diabetes patients

08/24/2011 | Medscape (free registration)

Metformin-treated patients with diabetes who were on adjuvant chemotherapy for triple-negative breast cancer had an overall survival rate of 67%, while those in the nontreated and no-diabetes groups had 69% and 66% OS rates respectively, a study in Cancer found. The findings, however, did suggest a lower risk of developing distant metastasis in diabetic patients taking metformin compared with nondiabetic patients, the researchers said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO